Platelet RNA Biomarker of Ticagrelor-Responsive Genes Is Associated With Platelet Function and Cardiovascular Events

• Published in: Arteriosclerosis, thrombosis, and vascular biology Vol. 44; no. 2; pp. 423 - 434
• Main Authors: Myers, Rachel A, Ortel, Thomas L, Waldrop, Alexander, Cornwell, MacIntosh, Newman, Jonathan D, Levy, Natalie K, Barrett, Tessa J, Ruggles, Kelly, Sowa, Marcin A, Dave, Sandeep, Ginsburg, Geoffrey S, Berger, Jeffrey S, Voora, Deepak
• Format: Journal Article
• Language: English
• Published: United States 01.02.2024
• Subjects: precision medicine; heart disease risk factors; biomarkers; hemorrhage; platelet aggregation inhibitor
• ISSN: 1079-5642; 1524-4636
• DOI: 10.1161/ATVBAHA.123.319759

Identifying patients with the optimal risk:benefit for ticagrelor is challenging. The aim was to identify ticagrelor-responsive platelet transcripts as biomarkers of platelet function and cardiovascular risk. Healthy volunteers (n=58, discovery; n=49, validation) were exposed to 4 weeks of ticagrelor with platelet RNA data, platelet function, and self-reported bleeding measured pre-/post-ticagrelor. RNA sequencing was used to discover platelet genes affected by ticagrelor, and a subset of the most informative was summarized into a composite score and tested for validation. This score was further analyzed (1) in CD34+ megakaryocytes exposed to an P2Y12 inhibitor in vitro, (2) with baseline platelet function in healthy controls, (3) in peripheral artery disease patients (n=139) versus patient controls (n=30) without atherosclerosis, and (4) in patients with peripheral artery disease for correlation with atherosclerosis severity and risk of incident major adverse cardiovascular and limb events. Ticagrelor exposure differentially expressed 3409 platelet transcripts. Of these, 111 were prioritized to calculate a Ticagrelor Exposure Signature score, which ticagrelor reproducibly increased in discovery and validation cohorts. Ticagrelor's effects on platelets transcripts positively correlated with effects of P2Y12 inhibition in primary megakaryocytes. In healthy controls, higher baseline scores correlated with lower baseline platelet function and with minor bleeding while receiving ticagrelor. In patients, lower scores independently associated with both the presence and extent of atherosclerosis and incident ischemic events. Ticagrelor-responsive platelet transcripts are a biomarker for platelet function and cardiovascular risk and may have clinical utility for selecting patients with optimal risk:benefit for ticagrelor use.